Medicine and Health

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

P. G. M. D. Gooyer, Y. L. Verschoor, et al.

In a phase 2 trial (NICHE-3), researchers investigated the remarkable effectiveness of neoadjuvant nivolumab combined with relatlimab in patients with locally advanced mismatch repair-deficient colon cancer. With a staggering 97% achieving a pathologic response, including 68% demonstrating complete responses, these findings highlight the therapy's promise for further studies. This groundbreaking research was conducted by Peter G. M. de Gooyer and colleagues from the Netherlands Cancer Institute.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

R. J. Kelly, B. V. Landon, et al.

Medicine and Health

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

M. Schuler, K. Cuppens, et al.

Medicine and Health

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

B. Besse, E. Pons-tostivint, et al.

Medicine and Health

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial

T. Sonoda, Y. Umeda, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny